Alvotech And DKSH Partner On Adalimumab In Asia
After Deals In Canada, Europe And Israel, Alvotech Targets Asia
Alvotech has partnered with DKSH to bring its high-concentration Humira rival to Asia. The Alvogen sister company plans to file the adalimumab biosimilar with the EMA and FDA in the second half of 2020.
You may also be interested in...
Alvotech and JAMP Pharma have struck a partnership deal to market five biosimilars in Canada that have a combined current branded market value of more than $2bn annually.
Israel’s Kamada has struck a licensing deal with Alvotech that gives it rights to several of the firm’s biosimilars in its domestic market. The first launch, of the teriparatide biosimilar co-developed with Pfenex, is planned for 2022.
Alvotech and Stada have struck a deal that will give Stada exclusive rights to sell seven Alvotech biosimilars “in all key European markets” as well as certain other territories.